-
1دورية أكاديمية
المؤلفون: A. N. Useinova, V. B. Kaliberdenko, S. P. Maryanenko, J. M. Al-Nsour, A. A. Korenkova, А. Н. Усеинова, В. Б. Калиберденко, С. П. Марьяненко, Дж. М. Аль-Нсоур, А. А. Коренькова
المصدر: Siberian journal of oncology; Том 23, № 3 (2024); 159-167 ; Сибирский онкологический журнал; Том 23, № 3 (2024); 159-167 ; 2312-3168 ; 1814-4861
مصطلحات موضوعية: доказательная медицина, chemotherapy, selective estrogen receptor modulators, selective estrogen receptor degrader, evidence-based medicine, химиотерапия, селективные модуляторы рецепторов эстрогена, селективный деструктор рецепторов эстрогена
وصف الملف: application/pdf
العلاقة: https://www.siboncoj.ru/jour/article/view/3126/1243Test; International agency for research on cancer [Internet]. World Health Organization. [cited 2023 Nov 15]. URL: https://gco.iarc.frTest/.; Рак молочной железы [Internet]. Всемирная организация здравоохранения [cited 2023 Nov 18]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancerTest.; Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., Boyle F., Cardoso M.J., Carey L.A., Cortés J., El Saghir N.S., Elzayat M., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Gligorov J., Haidinger R., Harbeck N., Hu X., Kaufman B., Kaur R., Kiely B.E., Kim S.B., Lin N.U., Mertz S.A., Neciosup S., Offersen B.V., Ohno S., Pagani O., Prat A., Penault-Llorca F., Rugo H.S., Sledge G.W., Thomssen C., Vorobiof D.A., Wiseman T., Xu B., Norton L., Costa A., Winer E.P. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623–49. doi:10.1016/j.annonc.2020.09.010.; Takada M., Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020; 9(3): 32. doi:10.21037/cco-20-123.; Rugo H.S., Rumble R.B., Macrae E., Barton D.L., Connolly H.K., Dickler M.N., Fallowfield L., Fowble B., Ingle J.N., Jahanzeb M., Johnston S.R., Korde L.A., Khatcheressian J.L., Mehta R.S., Muss H.B., Burstein H.J. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016; 34(25): 3069–103. doi:10.1200/JCO.2016.67.1487.; Shagufta Ahmad I. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018; 143: 515–31. doi:10.1016/j.ejmech.2017.11.056.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341–52. doi:10.1016/S0140-6736(15)61074-1.; Hong J., Huang J., Shen L., Zhu S., Gao W., Wu J., Huang O., He J., Zhu L., Chen W., Li Y., Chen X., Shen K. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer. 2020; 20(1): 663. doi:10.1186/s12885-020-07156-x.; Lainé M., Fanning S.W., Chang Y.F., Green B., Greene M.E., Komm B., Kurleto J.D., Phung L., Greene G.L. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021; 23(1): 54. doi:10.1186/s13058-021-01431-w.; Goetz M.P., Bagegni N.A., Batist G., Brufsky A., Cristofanilli M.A., Damodaran S., Daniel B.R., Fleming G.F., Gradishar W.J., Graff S.L., Grosse Perdekamp M.T., Hamilton E., Lavasani S., Moreno-Aspitia A., O’Connor T., Pluard T.J., Rugo H.S., Sammons S.L., Schwartzberg L.S., Stover D.G., Vidal G.A., Wang G., Warner E., Yerushalmi R., Plourde P.V., Portman D.J., Gal-Yam E.N. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023; 34(12): 1141–51. doi:10.1016/j.annonc.2023.09.3104.; Motlani G., Motlani V., Acharya N., Dave A., Pamnani S., Somyani D., Agrawal S. Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift. Cureus. 2023; 15(11). doi:10.7759/cureus.49079.; Perrone F., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M.G., Riccardi F., Russo A., Del Mastro L., Cogoni A.A., Cognetti F., Gori S., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Nuzzo F., Carlini P., De Placido S., On Behalf of GIM Investigators. Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial. Ann Oncol. 2017; 35. doi:10.1200/JCO.2017.35.15_suppl.515.; Garcia-Martinez L., Zhang Y., Nakata Y., Chan H.L., Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021; 12(1): 1786. doi:10.1038/s41467-021-22024-3.; Glück S. Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. Clin Breast Cancer. 2017; 17(2): 79–90. doi:10.1016/j.clbc.2016.08.004.; Akça K.T., Demirel M.A., Süntar I. The Role of Aromatase Enzyme in Hormone Related Diseases and Plant-Based Aromatase Inhibitors as Therapeutic Regimens. Curr Top Med Chem. 2022; 22(3): 229–46. doi:10.2174/1568026621666211129141631.; Wang Y., Jing F., Wang H. Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. Adv Ther. 2022; 39(2): 862–91. doi:10.1007/s12325-021-01924-2.; Zucchini G., Geuna E., Milani A., Aversa C., Martinello R., Montemurro F. Clinical utility of exemestane in the treatment of breast cancer. Int J Womens Health. 2015; 7: 551–63. doi:10.2147/IJWH.S69475.; Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Fowst C., Huang X., Kim S.T., Randolph S., Slamon D.J. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015; 16(1): 25–35. doi:10.1016/S1470-2045(14)71159-3.; Braal C.L., Jongbloed E.M., Wilting S.M., Mathijssen R.H.J., Koolen S.L.W., Jager A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021; 81(3): 317–31. doi:10.1007/s40265-020-01461-2.; Notaro U.S., Huber E., Stassi A.F., Ormaechea N.E., Chiaraviglio J.A., Baravalle M.E., Ortega H.H., Rey F., Salvetti N.R. Estrogens receptors, nuclear coactivator 1 and ligand-dependent corepressor expression are altered early during induced ovarian follicular persistence in dairy cattle. Theriogenology. 2023; 210: 17–27. doi:10.1016/j.theriogenology.2023.07.004.; Brufsky A.M., Dickler M.N. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist. 2018; 23(5): 528–39. doi:10.1634/theoncologist.2017-0423.; Dickler M.N., Tolaney S.M., Rugo H.S., Cortés J., Diéras V., Patt D., Wildiers H., Hudis C.A., O’Shaughnessy J., Zamora E., Yardley D.A., Frenzel M., Koustenis A., Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(17): 5218–24. doi:10.1158/1078-0432.CCR-17-0754. Erratum in: Clin Cancer Res. 2018; 24(21): 5485.; Gnant M., Dueck A.C., Frantal S., Martin M., Burstein H.J., Greil R., Fox P., Wolff A.C., Chan A., Winer E.P., Pfeiler G., Miller K.D., Colleoni M., Suga J.M., Rubovsky G., Bliss J.M., Mayer I.A., Singer C.F., Nowecki Z., Hahn O., Thomson J., Wolmark N., Amillano K., Rugo H.S., Steger G.G., Hernando Fernández de Aránguiz B., Haddad T.C., Perelló A., Bellet M., Fohler H., Metzger Filho O., Jallitsch-Halper A., Solomon K., Schurmans C., Theall K.P., Lu D.R., Tenner K., Fesl C., DeMichele A., Mayer E.L; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022; 40(3): 282–93. doi:10.1200/JCO.21.02554.; Rugo H.S., Im S.A., Joy A.A., Shparyk Y., Walshe J.M., Sleckman B., Loi S., Theall K.P., Kim S., Huang X., Bananis E., Mahtani R., Finn R.S., Diéras V. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022; 66: 324–31. doi:10.1016/j.breast.2022.11.005.; Xu B., Hu X., Li W., Sun T., Shen K., Wang S., Cheng Y., Zhang Q., Cui S., Tong Z., Geng C., Song E., Huang C.S., Sriuranpong V., Ngan R.K.C., Chia Y.H., Wang X., Zhao H. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022; 175: 236–45. doi:10.1016/j.ejca.2022.08.012.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Hart L., Campone M., Petrakova K., Winer E.P., Janni W., Conte P., Cameron D.A., André F., Arteaga C.L., Zarate J.P., Chakravartty A., Taran T., Le Gac F., Serra P., O’Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022; 386(10): 942–50. doi:10.1056/NEJMoa2114663.; Ji J., Zhang Z., He X., Pan G., Li G., Lv J., Xu Y., Xie M., Feng J., Wang W., Liu B., Ma J., Wang X. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6. Anticancer Drugs. 2023; 34(7): 803–15. doi:10.1097/CAD.0000000000001475.; Cristofanilli M., Rugo H.S., Im S.A., Slamon D.J., Harbeck N., Bondarenko I., Masuda N., Colleoni M., DeMichele A., Loi S., Iwata H., O’Leary B., André F., Loibl S., Bananis E., Liu Y., Huang X., Kim S., Lechuga Frean M.J., Turner N.C. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022; 28(16): 3433–42. doi:10.1158/1078-0432.CCR-22-0305.; Johnston S.R.D., Harbeck N., Hegg R., Toi M., Martin M., Shao Z.M., Zhang Q.Y., Martinez Rodriguez J.L., Campone M., Hamilton E., Sohn J., Guarneri V., Okada M., Boyle F., Neven P., Cortés J., Huober J., Wardley A., Tolaney S.M., Cicin I., Smith I.C., Frenzel M., Headley D., Wei R., San Antonio B., Hulstijn M., Cox J., O’Shaughnessy J., Rastogi P.; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, NodePositive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020; 38(34): 3987–98. doi:10.1200/JCO.20.02514.; Johnston S.R.D., Toi M., O’Shaughnessy J., Rastogi P., Campone M., Neven P., Huang C.S., Huober J., Jaliffe G.G., Cicin I., Tolaney S.M., Goetz M.P., Rugo H.S., Senkus E., Testa L., Del Mastro L., Shimizu C., Wei R., Shahir A., Munoz M., San Antonio B., André V., Harbeck N., Martin M.; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023; 24(1): 77–90. doi:10.1016/S1470-2045(22)00694-5.; Sledge G.W. Jr, Toi M., Neven P., Sohn J., Inoue K., Pivot X., Burdaeva O., Okera M., Masuda N., Kaufman P.A., Koh H., Grischke E.M., Conte P., Lu Y., Barriga S., Hurt K., Frenzel M., Johnston S., Llombart-Cussac A. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020; 6(1): 116–24. Doi:10.1001/jamaoncol.2019.4782.; Moreau-Bachelard C., Robert M., Gourmelon C., Bourbouloux E., Patsouris A., Frenel J.S., Campone M. Evaluating everolimus for the treatment of breast cancer. Expert Opin Pharmacother. 2023; 24(10): 1105–11. doi:10.1080/14656566.2023.2214677.; Prat A., Brase J.C., Cheng Y., Nuciforo P., Paré L., Pascual T., Martínez D., Galván P., Vidal M., Adamo B., Hortobagyi G.N., Baselga J., Ciruelos E. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist. 2019; 24(7): 893–900. doi:10.1634/theoncologist.2018-0407.; Juric D., Rodon J., Tabernero J., Janku F., Burris H.A., Schellens J.H.M., Middleton M.R., Berlin J., Schuler M., Gil-Martin M., Rugo H.S., Seggewiss-Bernhardt R., Huang A., Bootle D., Demanse D., Blumenstein L., Coughlin C., Quadt C., Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018; 36(13): 1291–9. doi:10.1200/JCO.2017.72.7107. Erratum in: J ClinOncol. 2019; 37(4): 361. Erratum in: J Clin Oncol. 2019; 37(4): 361.; André F., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S., Iwata H., Conte P., Mayer I.A., Kaufman B., Yamashita T., Lu Y.S., Inoue K., Takahashi M., Pápai Z., Longin A.S., Mills D., Wilke C., Hirawat S., Juric D.; SOLAR-1 Study Group.Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20): 1929–40. doi:10.1056/NEJMoa1813904.; Andrikopoulou A., Chatzinikolaou S., Panourgias E., Kaparelou M., Liontos M., Dimopoulos M.A., Zagouri F. The emerging role of capivasertib in breast cancer. Breast. 2022; 63: 157–67. doi:10.1016/j.breast.2022.03.018.; Shagufta, Ahmad I., Mathew S., Rahman S. Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. RSC Med Chem. 2020; 11(4): 438–54. doi:10.1039/c9md00570f.; Llombart-Cussac A., Pérez-García J.M., Bellet M., Dalenc F., Gil-Gil M., Ruíz-Borrego M., Gavilá J., Sampayo-Cordero M., Aguirre E., Schmid P., Marmé F., Di Cosimo S., Gligorov J., Schneeweiss A., Albanell J., Zamora P., Wheatley D., Martínez-de Dueñas E., Amillano K., Malfettone A., Cortés J.; PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021; 7(12): 1791–9. doi:10.1001/jamaoncol.2021.4301. Erratum in: JAMA Oncol.2021; 7(11): 1729.; Ma C.X., Luo J., Freedman R.A., Pluard T.J., Nangia J.R., Lu J., Valdez-Albini F., Cobleigh M., Jones J.M., Lin N.U., Winer E.P., Marcom P.K., Thomas S., Anderson J., Haas B., Bucheit L., Bryce R., Lalani A.S., Carey L.A., Goetz M.P., Gao F., Kimmick G., Pegram M.D., Ellis M.J., Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022; 28(7): 1258–67. doi:10.1158/1078-0432.CCR-21-3418.; Huang J., Huang P., Shao X.Y., Sun Y., Lei L., Lou C.J., Ye W.W., Chen J.Q., Cao W.M., Huang Y., Zheng Y.B., Wang X.J., Chen Z.H. Efficacy of fulvestrant 500mg in Chinese postmenopausal women with advanced/ recurrent breast cancer and factors associated with prolonged time-totreatment failure: A retrospective case series. Medicine (Baltimore). 2020; 99(29). doi:10.1097/MD.0000000000020821.; Bidard F.C., Kaklamani V.G., Neven P., Streich G., Montero A.J., Forget F., Mouret-Reynier M.A., Sohn J.H., Taylor D., Harnden K.K., Khong H., Kocsis J., Dalenc F., Dillon P.M., Babu S., Waters S., Deleu I., García Sáenz J.A., Bria E., Cazzaniga M., Lu J., Aftimos P., Cortés J., Liu S., Tonini G., Laurent D., Habboubi N., Conlan M.G., Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022; 40(28): 3246–56. doi:10.1200/JCO.22.00338. Erratum in: J Clin Oncol. 2023; 41(23): 3962.; Bardia A., Chandarlapaty S., Linden H.M., Ulaner G.A., Gosselin A., Cartot-Cotton S., Cohen P., Doroumian S., Paux G., Celanovic M., Pelekanou V., Ming J.E., Ternès N., Bouaboula M., Lee J.S., Bauchet A.L., Campone M. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun. 2022; 13(1): 4116. doi:10.1038/s41467-022-31668-8.; Campone M., Bidard F.C., Neven P., Wang L., Ling B., Dong Y., Paux G., Herold C., De Giorgi U. AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Res. 2023; 25(1): 141. doi:10.1186/s13058-023-01740-2.; Hurvitz S.A., Bardia A., Quiroga V., Park Y.H., Blancas I., Alonso-Romero J.L., Vasiliev A., Adamchuk H., Salgado M., Yardley D.A., Berzoy O., Zamora-Auñón P., Chan D., Spera G., Xue C., Ferreira E., Badovinac Crnjevic T., Pérez-Moreno P.D., López-Valverde V., Steinseifer J., Fernando T.M., Moore H.M., Fasching P.A.; coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023; 24(9): 1029–41. doi:10.1016/S1470-2045(23)00268-1. Erratum in: Lancet Oncol. 2023; 24(11).; Smith I., Robertson J., Kilburn L., Wilcox M., Evans A., Holcombe C., Horgan K., Kirwan C., Mallon E., Sibbering M., Skene A., Vidya R., Cheang M., Banerji J., Morden J., Sidhu K., Dodson A., Bliss J.M., Dowsett M. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020; 21(11): 1443–54. doi:10.1016/S1470-2045(20)30458-7. Erratum in: Lancet Oncol. 2020; 21(12).; Jhaveri K., Juric D., Yap Y.S., Cresta S., Layman R.M., Duhoux F.P., Terret C., Takahashi S., Huober J., Kundamal N., Sheng Q., Balbin A., Ji Y., He W., Crystal A., De Vita S., Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2021; 27(21): 5760–70. doi:10.1158/1078-0432.CCR-21-1095.; Qin H., Zhang Y., Lou Y., Pan Z., Song F., Liu Y., Xu T., Zheng X., Hu X., Huang P. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery. Curr Med Chem. 2022; 29(22): 3922–44. doi:10.2174/0929867328666211110101018.; Puyang X., Furman C., Zheng G.Z., Wu Z.J., Banka D., Aithal K., Agoulnik S., Bolduc D.M., Buonamici S., Caleb B., Das S., Eckley S., Fekkes P., Hao M.H., Hart A., Houtman R., Irwin S., Joshi J.J., Karr C., Kim A., Kumar N., Kumar P., Kuznetsov G., Lai W.G., Larsen N., Mackenzie C., Martin L.A., Melchers D., Moriarty A., Nguyen T.V., Norris J., O’Shea M., Pancholi S., Prajapati S., Rajagopalan S., Reynolds D.J., Rimkunas V., Rioux N., Ribas R., Siu A., Sivakumar S., Subramanian V., Thomas M., Vaillancourt F.H., Wang J., Wardell S., Wick M.J., Yao S., Yu L., Warmuth M., Smith P.G., Zhu P., Korpal M. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ErαWT and ERαMUT Breast Cancer. Cancer Discov. 2018; 8(9): 1176–93. doi:10.1158/2159-8290.CD-17-1229.; Gu G., Tian L., Herzog S.K., Rechoum Y., Gelsomino L., Gao M., Du L., Kim J.A., Dustin D., Lo H.C., Beyer A.R., Edwards D.G., Gonzalez T., Tsimelzon A., Huang H.J., Fernandez N.M., Grimm S.L., Hilsenbeck S.G., Liu D., Xu J., Alaniz A., Li S., Mills G.B., Janku F., Kittler R., Zhang X.H., Coarfa C., Foulds C.E., Symmans W.F., Andò S., Fuqua S.A.W. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021; 40(5): 997–1011. doi:10.1038/s41388-020-01563-x. Erratum in: Oncogene. 2022; 41(3): 460.; https://www.siboncoj.ru/jour/article/view/3126Test
الإتاحة: https://doi.org/10.21294/1814-4861-2024-23-3-159-16710.1016/j.annonc.2020.09.01010.21037/cco-20-12310.1200/JCO.2016.67.148710.1016/j.ejmech.2017.11.05610.1016/S0140-6736Test(15)61074-110.1186/s12885-020-07156-x10.1186/s13058-021-01431-w10.1016/j.annonc.2023.09.310410.7759/cureus.4907910.1200/JCO.2017.35.15_suppl.51510.1038/s41467-021-22024-310.1016/j.clbc.2016.08.00410.2174/156802662166621112914163110.1007/s12325-021-01924-210.2147/IJWH.S6947510.1016/S1470-2045(14)71159-310.1007/s40265-020-01461-210.1016/j.theriogenology.2023.07.00410.1634/theoncologist.2017-042310.1158/1078-0432.CCR-17-075410.1200/JCO.21.0255410.1016/j.breast.2022.11.00510.1016/j.ejca.2022.08.01210.1056/NEJMoa211466310.1097/CAD.000000000000147510.1158/1078-0432.CCR-22-030510.1200/JCO.20.0251410.1016/S1470-2045(22)00694-510.1001/jamaoncol.2019.478210.1080/14656566.2023.221467710.1634/theoncologist.2018-040710.1200/JCO.2017.72.710710.1056/NEJMoa181390410.1016/j.breast.2022.03.01810.1039/c9md00570f10.1001/jamaoncol.2021.430110.1158/1078-0432.CCR-21-341810.1097/MD.000000000002082110.1200/JCO.22.0033810.1038/s41467-022-31668-810.1186/s13058-023-01740-210.1016/S1470-2045(23)00268-110.1016/S1470-2045(20)30458-710.1158/1078-0432.CCR-21-109510.2174/092986732866621111010101810.1158/2159-8290.CD-17-122910.1038/s41388-020-01563-x
https://www.siboncoj.ru/jour/article/view/3126Test -
2دورية أكاديمية
المؤلفون: Bardia, Aditya, Cortes, Javier, Hurvitz, Sara A, Delaloge, Suzette, Iwata, Hiroji, Shao, Zhi-Ming, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O’Shaughnessy, Joyce
مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Aging, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Estrogen, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, amcenestrant, endocrine therapy, ER-positive, HER2-negative, metastatic breast cancer, selective estrogen receptor degrader, ER-positive/HER2-negative, Oncology and carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/5v2490r1Test
-
3دورية أكاديمية
المصدر: Frontiers in Pharmacology, Vol 14 (2023)
مصطلحات موضوعية: estrogen receptor, selective estrogen receptor degrader, selective estrogen receptor covalent antagonist, structural optimization, small molecule drugs, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1225951/fullTest; https://doaj.org/toc/1663-9812Test
-
4دورية أكاديمية
المؤلفون: Turner N., Huang-Bartlett C., Kalinsky K., Cristofanilli M., Bianchini G., Chia S., Iwata H., Janni W., Ma C. X., Mayer E. L., Park Y. H., Fox S., Liu X., Mcclain S., Bidard F. -C.
المساهمون: Turner, N., Huang-Bartlett, C., Kalinsky, K., Cristofanilli, M., Bianchini, G., Chia, S., Iwata, H., Janni, W., Ma, C. X., Mayer, E. L., Park, Y. H., Fox, S., Liu, X., Mcclain, S., Bidard, F. -C.
مصطلحات موضوعية: advanced breast cancer, camizestrant, circulating tumor DNA, endocrine therapy resistance, ESR1 mutation, hormone-receptor-positive breast cancer, selective estrogen receptor degrader
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37070653; info:eu-repo/semantics/altIdentifier/wos/WOS:000973642100001; volume:19; issue:8; firstpage:559; lastpage:573; numberofpages:15; journal:FUTURE ONCOLOGY; https://hdl.handle.net/20.500.11768/161517Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159189798
الإتاحة: https://doi.org/20.500.11768/16151710.2217/fon-2022-1196Test
https://hdl.handle.net/20.500.11768/161517Test -
5دورية أكاديمية
المؤلفون: Dubash, Taronish T.D., Bardia, Aditya, Chirn, Brian, Reeves, Brittany B.A., LiCausi, Joseph J.A., Burr, Risa, Wittner, Ben, Rai, Sumit, Patel, Hitisha, Bihani, Teeru, Arlt, Heike, Bidard, François-Clément, Kaklamani, Virginia V.G., Aftimos, Philippe, Cortes, Javier, Scartoni, Simona, Fiascarelli, Alessio, Binaschi, Monica, Habboubi, Nassir, Iafrate, Anthony John, Toner, Mehmet, Haber, Daniel D.A., Maheswaran, Shyamala
المصدر: Breast cancer research and treatment, 201 (1
مصطلحات موضوعية: Cancérologie, Circulating tumor cells (CTCs), Elacestrant, ER + metastatic breast cancer, Fulvestrant resistance, Selective estrogen receptor degrader (SERD)
وصف الملف: 1 full-text file(s): application/pdf
العلاقة: uri/info:doi/10.1007/s10549-023-06998-w; uri/info:pmid/37318638; uri/info:scp/85162032401; https://dipot.ulb.ac.be/dspace/bitstream/2013/372377/1/doi_356021.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/372377Test
-
6دورية أكاديمية
المؤلفون: Jun Liang (251318), Jason R. Zbieg (1892965), Robert A. Blake (8974823), Jae H. Chang (1429789), Stephen Daly (2430460), Antonio G. DiPasquale (1274730), Lori S. Friedman (166879), Thomas Gelzleichter (11113391), Matthew Gill (589302), Jennifer M. Giltnane (11113394), Simon Goodacre (1577413), Jane Guan (166826), Steven J. Hartman (10157036), Ellen Rei Ingalla (8908757), Lorn Kategaya (11113397), James R. Kiefer (1443889), Tracy Kleinheinz (1845637), Sharada S. Labadie (1833826), Tommy Lai (2572615), Jun Li (6494), Jiangpeng Liao (1947631), Zhiguo Liu (594653), Vidhi Mody (8908760), Neville McLean (2128303), Ciara Metcalfe (8908763), Michelle A. Nannini (11113400), Jason Oeh (1845505), Martin G. O’Rourke (11113403), Daniel F. Ortwine (1600621), Yingqing Ran (2100610), Nicholas C. Ray (3064926), Fabien Roussel (3030714), Amy Sambrone (1551289), Deepak Sampath (640340), Leah K. Schutt (11113406), Maia Vinogradova (8908772), John Wai (1503217), Tao Wang (12008), Ingrid E. Wertz (11113409), Jonathan R. White (11113412), Siew Kuen Yeap (1346391), Amy Young (251900), Birong Zhang (1947472), Xiaoping Zheng (566379), Wei Zhou (24328), Yu Zhong (291917), Xiaojing Wang (147040)
مصطلحات موضوعية: Cell Biology, Genetics, Neuroscience, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Exceptional Preclinical Profile, dose, Bioavailable, human, candidate, combination, liability, Phase, Orally, antagonist, Breast Cancer Breast cancer, wild-type ER α tumor model, GDC -9545, estrogen receptor degrader, antiproliferation, SERD, interaction, Estrogen Receptor Antagonist, giredestrant, Fine-tuning, PDX
-
7دورية أكاديمية
المؤلفون: Anastasia Kapara (10522363), Karla A. Findlay Paterson (10522366), Valerie G. Brunton (7325402), Duncan Graham (577906), Michele Zagnoni (1333761), Karen Faulds (577905)
مصطلحات موضوعية: Medicine, Cell Biology, Molecular Biology, Pharmacology, Biotechnology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 3 D tumor model, ER α-AuNP nanotags, ER α, 3 D tumor models, microfluidic technologies, target ER α. Mixtures, breast cancer cell line MCF -7, HER 2-AuNPs, chemical reporters, estrogen receptor, estrogen receptor degrader, SERD activity, tumor models, ER α-positive, multiplexed nanoparticle-based assays, MCF -7 cells, anti-ER α antibody-functionalized n., 3 D SERS measurements, microfluidic devices, cancer phenotype, epidermal growth factor receptor 2, Raman reporters
-
8دورية أكاديمية
المؤلفون: Jiawang Liu, Nirmal Rajasekaran, Ahamed Hossain, Changde Zhang, Shanchun Guo, Borui Kang, Hunsoon Jung, Hongjoong Kim, Guangdi Wang
المصدر: Pharmaceuticals; Volume 14; Issue 8; Pages: 719
مصطلحات موضوعية: selective estrogen receptor degrader, ZB716, pharmacokinetics, oral bioavailability, breast cancer, fulvestrant
وصف الملف: application/pdf
-
9دورية أكاديمية
المؤلفون: Sean W Fanning, Rinath Jeselsohn, Venkatasubramanian Dharmarajan, Christopher G Mayne, Mostafa Karimi, Gilles Buchwalter, René Houtman, Weiyi Toy, Colin E Fowler, Ross Han, Muriel Lainé, Kathryn E Carlson, Teresa A Martin, Jason Nowak, Jerome C Nwachukwu, David J Hosfield, Sarat Chandarlapaty, Emad Tajkhorshid, Kendall W Nettles, Patrick R Griffin, Yang Shen, John A Katzenellenbogen, Myles Brown, Geoffrey L Greene
المصدر: eLife, Vol 7 (2018)
مصطلحات موضوعية: breast cancer, acquired drug resistance, hormone therapy, ESR1 Somatic Mutation, estrogen receptor, selective estrogen receptor Degrader, Medicine, Science, Biology (General), QH301-705.5
وصف الملف: electronic resource
-
10
المؤلفون: Yueh-Te Lin, Joseph Lin, Yi-En Liu, Kai-Wen Hsu, Chang-Chi Hsieh, Dar-Ren Chen, Han-Tsang Wu
المصدر: Translational Oncology, Vol 15, Iss 1, Pp 101302-(2022)
Translational Oncologyمصطلحات موضوعية: Cancer Research, MMP, mitochondrial membrane potential, ER, estrogen receptor, BC, breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, NM, nafamostat mesylate, SERD, selective estrogen receptor degrader, PFS, progression-free survival, SERM, selective ER modulator, Oncology, ERPBC, estrogen receptor-positive breast cancer, Nafamostat mesylate, CDK4/6, Estrogen receptor-positive breast cancer, EMT, epithelial-mesenchymal transition, RC254-282, Original Research, Endocrine resistance
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be9e51d18156f766d815114a7d19d38Test
http://www.sciencedirect.com/science/article/pii/S193652332100293XTest
النص الكامل